All In Biotech

NDA 211964 · Supernus Pharms

Qelbree

Viloxazine Hydrochloride · Oral

Novel

CDER novel approval, Apr 2, 2021: To treat attention deficit hyperactivity disorder

Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Apr 2, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

8 Phase 3, 1 recruiting

FAERS reports

1,309

400 serious, 10 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS In clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with ADHD treated with Qelbree than in patients treated with placebo . Closely monitor all Qelbree-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. In clinical trials, higher rates of suicidal thoughts and behavior were reported in patients treated with Qelbree than in patients treated with placebo. Closely monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ).

What it is approved for

From the label in effect Oct 5, 2026.

Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older ( 1 )

Mechanism: The mechanism of action of viloxazine in the treatment of ADHD is unclear; however, it is thought to be through inhibiting the reuptake of norepinephrine.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • QELBREE · VILOXAZINE HYDROCHLORIDE EQ 200MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • QELBREE · VILOXAZINE HYDROCHLORIDE EQ 100MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • QELBREE · VILOXAZINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Viloxazine" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache146
  • vomiting132
  • nausea130
  • migraine124
  • fatigue109
  • insomnia109
  • somnolence87
  • drug ineffective82
  • suicidal ideation82
  • withdrawal syndrome57
  • anxiety56
  • product dose omission issue51

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20134
20201
202153
2022215
2023204
2024186
2025285
2026361

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qelbree (Viloxazine HCl)

2024 spending

$6.8M

Beneficiaries

3,232

11,851 claims

Per beneficiary

$2,103

$11.84 per unit

View as table
YearSpending
2020$0
2021$34,881
2022$1,045,765
2023$4,086,858
2024$6,796,781

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: Supernus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.